Evidence map›Paper›PMID 36709150›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma].

W Q Yao, L Z Yan, J J Shang, S Jin, X L Shi, S Yan, Z Yan, Q Q Wang, C C Fu, D P Wu

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

W Q YaoThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
L Z YanThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
J J ShangThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
S JinThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
X L ShiThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
S YanThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
Z YanThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
Q Q WangThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
C C FuThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
D P WuThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215000, China.
First Affiliated Hospital of Soochow University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaNeutropeniaThrombocytopeniaAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDiarrheaHumansInduction ChemotherapyLenalidomideTransplantation, AutologousBortezomibDexamethasoneLenalidomideBortezomibLenalidomideMultiple myeloma

Identifiers

PMID36709150
PMCPMC9593008
OpenAlexW4318450580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.